Product name
Recombinant Human BCMA protein
Code
CD02272
Biological activity
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated Mouse B cells is no less than 40 ng/ml, corresponding to a specific activity of > 2.5 × 104 IU/mg in the presence of 100 ng/ml human APRIL.
Endotoxin
Less than 1 EU/μg of rHuBCMA as determined by LAL method.
Synonyms
TNFRSF17,BCM, BCMA, CD269, TNFRSF13A, Human
Sequence
AGQCSQNEYF DSLLHACIPC QLRCSSNTPP LTCQRYCNAS VTNSVKGTNA
Uniprot Accession
Molecular Weight
Approximately 5.4 kDa, a single non-glycosylated polypeptide chain containing 50 amino acids.
Formulation
Lyophilized from a 0.2 μm filtered concentrated solution in 30 % acetonitrile, 0.1 % TFA.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Background
B-Cell Maturation Antigen (BCMA), encoded by the TNFRSF17 gene in humans. It is a member of the TNF receptor superfamily and a type III membrane protein containing one extracellular cysteine rich domain. It is expressed on mature B-cells and other B-cell lines. BCMA can binds to TNFSF13B/BLyS/BAFF and TNFSF13/APRIL, and has functions that promotes B-cell survival, plays a role in the regulation of humoral immunity, and activates NF-kappa-B and JNK BCMA.
Storage
-20ºC
Research area
Immunology
